JAVELIN ONCOLOGY
Javelin Oncology is a pharmaceutical company that provides a new capability to precision immune medicine and design effective therapies.
JAVELIN ONCOLOGY
Industry:
Alternative Medicine Biotechnology Health Care Pharmaceutical
Address:
Lebanon, New Hampshire, United States
Country:
United States
Website Url:
http://www.javelinoncology.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Google Maps GoDaddy DNS Google Google Cloud WP Engine Google Cloud South Carolina
Similar Organizations
Auromedics Pharma
Auromedics Pharma is generic injectables company that has built its business and offerings around servicing located in East Windsor.
Maver Laboratories
Maver is an all-encompassing corporation that produces and distributes high-quality medicine using cutting-edge technologies.
Taiho Oncology
Taiho Oncology is a pharmaceutical company that specializes in developing innovative cancer treatments.
Current Employees Featured
Founder
Official Site Inspections
http://www.javelinoncology.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Javelin Oncology"
Javelin Oncology - Crunchbase Company Profile & Funding
Javelin Oncology is a pharmaceutical company that provides a new capability to precision immune medicine and design effective therapies. Search Crunchbase. ... 128 Number of …See details»
Javelin Oncology Company Profile | Management and Employees …
Javelin Oncology Profile and History Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own …See details»
Javelin Oncology - Overview, News & Similar companies - ZoomInfo
Javelin Oncology contact info: Phone number: (617) 320-8521 Website: www.javelinoncology.com What does Javelin Oncology do? Javelin Oncology is a leader in precision immune medicine. …See details»
Javelin Oncology, Inc Company Profile - Dun & Bradstreet
Javelin Oncology, Inc. D&B Business Directory HOME / BUSINESS DIRECTORY / PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES / SCIENTIFIC RESEARCH …See details»
Javelin Oncology - Products, Competitors, Financials, Employees ...
About Javelin Oncology Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts …See details»
Javelin Oncology Inc | www.inknowvation.com
State Support Organizations; Prof. Service Providers; Venture Capitalists; Academics; Analytics. About Analytics; State Office; Federal Agency Office; Tech Seekers (TS) ... Javelin Oncology …See details»
Javelin Oncology, Inc. - Virtici
Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular …See details»
Avelumab First-Line Maintenance for Advanced Urothelial …
Jul 3, 2023 INTRODUCTION. In the phase III JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and …See details»
Aclys Bio — Building Precision Antibodies to Treat Cancer Patients
Aclys builds antibodies specifically designed for precision applications. Precision oncology provides significant benefits including, higher efficacy, smaller trial size, lower trial cost, faster …See details»
Javelin Biotech
Drug Discovery. Humanized. Javelin Biotech creates predictive drug discovery platforms that merge human biology with computational biology to accelerate preclinical drug discovery and …See details»
Avelumab first-line maintenance therapy for locally …
Jan 29, 2024 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance (AVE 1LM) + best supportive care (BSC) improved overall survival (OS) and …See details»
JAVELIN Bladder 100 Study in Advanced Urothelial Cancer
Aug 26, 2021 If I count correctly, this was the end of June 2020 after your oralpresentation at the planned session at ASCO [American Society of Clinical Oncology Annual Meeting] 2020. But …See details»
Avelumab first-line (1L) maintenance for advanced urothelial …
Jan 29, 2024 Background: Avelumab 1L maintenance is recommended as standard of care by international treatment guidelines for pts with aUC that has not progressed with 1L platinum …See details»
JAVELIN Bladder 100 Demonstrates Significantly Prolonged OS
Jun 10, 2020 First-line maintenance therapy with avelumab in patients with advanced urothelial cancer whose disease has not progressed with platinum-based induction chemotherapy …See details»
Getting the right combination to break the epigenetic code
3 days ago Increased recognition of the roles of epigenetic reprogramming in cancer has spurred the development of epigenetic therapies, although these drugs have meaningful …See details»
910O Primary results of the phase III JAVELIN head & neck 100 …
Despite high-dose, cisplatin-containing, multimodality therapy, LA SCCHN ultimately recurs in many patients. This trial investigated whether avelumab, a human anti–PD-L1 antibody, …See details»
Avelumab First-Line Maintenance for Advanced Urothelial …
Apr 18, 2023 The design of JAVELIN Bladder 100 (ClinicalTrials.gov identifier: NCT02603432) has been described previously. 1 Eligible patients had locally advanced or metastatic urothelial …See details»
JAVELIN Lung 100: updated design of a phase 3 ... - Annals of …
Background: Avelumab is a human anti–PD-L1 IgG1 antibody that has shown promising antitumor activity and manageable safety in several tumor types, including NSCLC, and is approved in …See details»
JAVELIN head and neck 100: A phase 3 trial of avelumab in …
May 30, 2017 Background: Cisplatin + radiotherapy is a standard-of-care treatment for patients (pts) with LA SCCHN. Combining avelumab (fully human IgG1 anti–PD-L1 antibody) and CRT …See details»
Updated efficacy results from the JAVELIN Renal 101 trial: first-line ...
Apr 24, 2020 The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib …See details»